Cargando…

Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome

BACKGROUND: Elevated levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 have been identified in fibromyalgia patients. AIMS: To examine the potential association among serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 with disease severity of fibromyalgia...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yuan-Chuang, Hu, Ting, Chen, Yan, Du, Ke-Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835162/
https://www.ncbi.nlm.nih.gov/pubmed/31486327
http://dx.doi.org/10.4274/balkanmedj.galenos.2019.2019.6.47
_version_ 1783466604082757632
author Zhao, Yuan-Chuang
Hu, Ting
Chen, Yan
Du, Ke-Tao
author_facet Zhao, Yuan-Chuang
Hu, Ting
Chen, Yan
Du, Ke-Tao
author_sort Zhao, Yuan-Chuang
collection PubMed
description BACKGROUND: Elevated levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 have been identified in fibromyalgia patients. AIMS: To examine the potential association among serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 with disease severity of fibromyalgia. STUDY DESIGN: Cross-sectional study. METHODS: Seventy-nine female patients with fibromyalgia and 75 healthy normal controls were included in our study. Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were detected by enzyme-linked immune sorbent assays. The existence of tender points was evaluated based on the standardized manual tender point examination. Pressure pain thresholds at the knees, and bilateral trapezius muscles were measured with an algometer. A visual analog scale and the Revised Fibromyalgia Impact Questionnaire were utilized to assess the degree of pain and functional abilities. RESULTS: Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were significantly greater in patients with fibromyalgia compared with healthy controls (151.6±31.9 pg/mL vs 103.3±25.2 pg/mL, p<0.001). Patients with severe fibromyalgia had significantly higher serum levels of chemokine C-C motif ligand 2 than patients with mild and moderate fibromyalgia (173.1±21.9 pg/mL vs 151.0.0±35.1 pg/mL, p=0.01). Patients with moderate fibromyalgia revealed markedly augmented serum levels of chemokine C-C motif ligand 2 compared with patients with mild fibromyalgia (151.0±35.1 pg/mL vs 133.3±23.9 pg/mL, p=0.03). Serum levels of chemokine C-C motif ligand 2 were positively associated with tender point scores (r=0.455, p<0.001). In addition, serum levels of chemokine C-C motif ligand 2 were positively associated with pressure pain thresholds in both knees and bilateral trapezius muscles (knees: r=-0.349, p=0.002; trapezius muscles: r=-0.318, p=0.004). Finally, we found elevated serum levels of chemokine C-C motif ligand were also positively associated with the visual analog scale (r=0.368, p=0.001), and the Fibromyalgia Impact Questionnaire score (r=0.401, p<0.001). CONCLUSION: Elevated serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 are linked to disease severity of fibromyalgia. Therapeutic interventions inhibiting monocyte chemotactic protein-1/chemokine C-C motif ligand 2 in fibromyalgia deserve additional studies.
format Online
Article
Text
id pubmed-6835162
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-68351622019-12-01 Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome Zhao, Yuan-Chuang Hu, Ting Chen, Yan Du, Ke-Tao Balkan Med J Original Article BACKGROUND: Elevated levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 have been identified in fibromyalgia patients. AIMS: To examine the potential association among serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 with disease severity of fibromyalgia. STUDY DESIGN: Cross-sectional study. METHODS: Seventy-nine female patients with fibromyalgia and 75 healthy normal controls were included in our study. Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were detected by enzyme-linked immune sorbent assays. The existence of tender points was evaluated based on the standardized manual tender point examination. Pressure pain thresholds at the knees, and bilateral trapezius muscles were measured with an algometer. A visual analog scale and the Revised Fibromyalgia Impact Questionnaire were utilized to assess the degree of pain and functional abilities. RESULTS: Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were significantly greater in patients with fibromyalgia compared with healthy controls (151.6±31.9 pg/mL vs 103.3±25.2 pg/mL, p<0.001). Patients with severe fibromyalgia had significantly higher serum levels of chemokine C-C motif ligand 2 than patients with mild and moderate fibromyalgia (173.1±21.9 pg/mL vs 151.0.0±35.1 pg/mL, p=0.01). Patients with moderate fibromyalgia revealed markedly augmented serum levels of chemokine C-C motif ligand 2 compared with patients with mild fibromyalgia (151.0±35.1 pg/mL vs 133.3±23.9 pg/mL, p=0.03). Serum levels of chemokine C-C motif ligand 2 were positively associated with tender point scores (r=0.455, p<0.001). In addition, serum levels of chemokine C-C motif ligand 2 were positively associated with pressure pain thresholds in both knees and bilateral trapezius muscles (knees: r=-0.349, p=0.002; trapezius muscles: r=-0.318, p=0.004). Finally, we found elevated serum levels of chemokine C-C motif ligand were also positively associated with the visual analog scale (r=0.368, p=0.001), and the Fibromyalgia Impact Questionnaire score (r=0.401, p<0.001). CONCLUSION: Elevated serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 are linked to disease severity of fibromyalgia. Therapeutic interventions inhibiting monocyte chemotactic protein-1/chemokine C-C motif ligand 2 in fibromyalgia deserve additional studies. Galenos Publishing 2019-12 2019-10-28 /pmc/articles/PMC6835162/ /pubmed/31486327 http://dx.doi.org/10.4274/balkanmedj.galenos.2019.2019.6.47 Text en ©Copyright 2019 by Trakya University Faculty of Medicine http://creativecommons.org/licenses/by/2.5/ The Balkan Medical Journal published by Galenos Publishing House.
spellingShingle Original Article
Zhao, Yuan-Chuang
Hu, Ting
Chen, Yan
Du, Ke-Tao
Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome
title Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome
title_full Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome
title_fullStr Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome
title_full_unstemmed Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome
title_short Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome
title_sort elevated serum levels of monocyte chemotactic protein-1/chemokine c-c motif ligand 2 are linked to disease severity in patients with fibromyalgia syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835162/
https://www.ncbi.nlm.nih.gov/pubmed/31486327
http://dx.doi.org/10.4274/balkanmedj.galenos.2019.2019.6.47
work_keys_str_mv AT zhaoyuanchuang elevatedserumlevelsofmonocytechemotacticprotein1chemokineccmotifligand2arelinkedtodiseaseseverityinpatientswithfibromyalgiasyndrome
AT huting elevatedserumlevelsofmonocytechemotacticprotein1chemokineccmotifligand2arelinkedtodiseaseseverityinpatientswithfibromyalgiasyndrome
AT chenyan elevatedserumlevelsofmonocytechemotacticprotein1chemokineccmotifligand2arelinkedtodiseaseseverityinpatientswithfibromyalgiasyndrome
AT duketao elevatedserumlevelsofmonocytechemotacticprotein1chemokineccmotifligand2arelinkedtodiseaseseverityinpatientswithfibromyalgiasyndrome